Digital Shift: CDSCO Mandates Online Submissions for r-DNA Post-Approval Changes

The Central Drugs Standard Control Organization (CDSCO), under the Government of India’s Directorate General of Health Services, has officially transitioned the regulatory process for recombinant DNA (r-DNA) products into a digital-only format. In a circular dated March 9, 2026, the Biological Division announced that all applications regarding Post Approval Changes (PAC) for Marketing Authorization (MA) must now be processed through the national online portal.

This move is part of a broader initiative to streamline regulatory submission procedures and enhance transparency within the pharmaceutical sector.

Transition to the SUGAM Portal

The primary change involves the mandatory use of the SUGAM Portal (www.cdscoonline.gov.in). Stakeholders are now required to submit their PAC applications specifically through the module titled "Post Approval Changes - MA". To ensure that submissions meet federal standards, applicants must strictly follow the checklist provided within that online module.

By centralizing these requests digitally, the CDSCO aims to create a more efficient review timeline for modifications to already-authorized r-DNA products.

Critical Deadlines for Stakeholders

The most vital takeaway for manufacturers and importers is the immediate cessation of manual filings. According to the directive issued by Dr. Rajeev Singh Raghuvanshi, the Drugs Controller General of India, the facility for offline submission of hard-copy applications was terminated on March 5, 2026.

Any application submitted in physical form after this cutoff date will no longer be available for processing. This underscores the urgency for all stakeholders to migrate their administrative workflows to the online system immediately.

Implementation and Enforcement

The circular (File No. r-DNA-15011(11)/72/2025-eoffice) has been disseminated to a wide range of regulatory and industry bodies to ensure total compliance:

• Zonal and Sub-Zonal Offices: All regional CDSCO offices have been notified to align their local operations with this digital mandate.
• Central Registration Unit (CRU): The headquarters’ registration section is now focused on managing the digital intake rather than physical documents.
• CDAC Team: The technical team responsible for the portal’s infrastructure is tasked with maintaining the functional stability of the r-DNA module.
• Industry Stakeholders: General notification has been provided through the official CDSCO website to reach all relevant pharmaceutical entities.

This administrative shift represents a significant step toward "Paperless Governance" in India's biotechnology regulation, ensuring that post-approval modifications—which are often critical for product safety and manufacturing efficiency—are handled with modern technical precision.